Respiratory health impacts quality of life for adults with OI

2019 ◽  
Author(s):  
Elizabeth Yonko ◽  
Erin Carter ◽  
Robert Sandhaus ◽  
Cathleen Raggio
2014 ◽  
Vol 103 (8) ◽  
pp. 850-855 ◽  
Author(s):  
Katri Backman ◽  
Eija Piippo-Savolainen ◽  
Hertta Ollikainen ◽  
Heikki Koskela ◽  
Matti Korppi

2014 ◽  
Vol 44 (4) ◽  
pp. 278-283 ◽  
Author(s):  
Mahmoud K. AL-Omiri ◽  
Jumana Karasneh ◽  
Mohannad M. Alhijawi ◽  
Abdalwhab M. A. Zwiri ◽  
Crispian Scully ◽  
...  

2014 ◽  
Vol 59 (2) ◽  
pp. 234-239 ◽  
Author(s):  
PJ Ford ◽  
S Cramb ◽  
CS Farah

2013 ◽  
Vol 36 (3) ◽  
pp. 460-466 ◽  
Author(s):  
Donee Alexander ◽  
Jacqueline Callihan Linnes ◽  
Susan Bolton ◽  
Timothy Larson

Breathe ◽  
2021 ◽  
Vol 17 (1) ◽  
pp. 210002
Author(s):  
Sonal Kansra ◽  
Rachel Calvert ◽  
Steve Jones

Children with respiratory diseases take treatments for the self-management of symptoms and to maintain disease control. Often, these treatments need to be taken in social environments like school. Respiratory treatments can foster a feeling of difference and stigmatisation, which negatively impact on the quality of life and adherence to treatment. Such perceptions can lead to a less than optimal disease control, a vicious cycle leading to further social exclusion and stigma. This aspect of “burden of treatment” is poorly recognised by clinicians. Recognition of how treatments and clinical practice can contribute to stigma, can help address this burden of care.Educational aimsTo understand the meaning of the term “stigma” within the context of respiratory health conditions and how medication or treatments can contribute to stigma in children and young people.To understand the potential impact of stigma on adherence, disease control and quality of life.To consider strategies to manage the stigma associated with health treatments across spheres of influence.


2019 ◽  
Vol Volume 14 ◽  
pp. 1813-1824 ◽  
Author(s):  
F.I. Hawari ◽  
N.A. Obeidat ◽  
M. Abu Alhalawa ◽  
Z. Al-Busaidi ◽  
B. Amara ◽  
...  

Thorax ◽  
2020 ◽  
Vol 75 (3) ◽  
pp. 279-288 ◽  
Author(s):  
Claire L Boswell-Ruys ◽  
Chaminda R H Lewis ◽  
Nirupama S Wijeysuriya ◽  
Rachel A McBain ◽  
Bonsan Bonne Lee ◽  
...  

BackgroundRespiratory complications remain a leading cause of morbidity and mortality in people with acute and chronic tetraplegia. Respiratory muscle weakness following spinal cord injury-induced tetraplegia impairs lung function and the ability to cough. In particular, inspiratory muscle strength has been identified as the best predictor of the likelihood of developing pneumonia in individuals with tetraplegia. We hypothesised that 6 weeks of progressive respiratory muscle training (RMT) increases respiratory muscle strength with improvements in lung function, quality of life and respiratory health.MethodsSixty-two adults with tetraplegia participated in a double-blind randomised controlled trial. Active or sham RMT was performed twice daily for 6 weeks. Inspiratory muscle strength, measured as maximal inspiratory pressure (PImax) was the primary outcome. Secondary outcomes included lung function, quality of life and respiratory health. Between-group comparisons were obtained with linear models adjusting for baseline values of the outcomes.ResultsAfter 6 weeks, there was a greater improvement in PImax in the active group than in the sham group (mean difference 11.5 cmH2O (95% CI 5.6 to 17.4), p<0.001) and respiratory symptoms were reduced (St George Respiratory Questionnaire mean difference 10.3 points (0.01–20.65), p=0.046). Significant improvements were observed in quality of life (EuroQol-Five Dimensional Visual Analogue Scale 14.9 points (1.9–27.9), p=0.023) and perceived breathlessness (Borg score 0.64 (0.11–1.17), p=0.021). There were no significant improvements in other measures of respiratory function (p=0.126–0.979).ConclusionsProgressive RMT increases inspiratory muscle strength in people with tetraplegia, by a magnitude which is likely to be clinically significant. Measurement of baseline PImax and provision of RMT to at-risk individuals may reduce respiratory complications after tetraplegia.Trial registration numberAustralian New Zealand Clinical Trials Registry (ACTRN 12612000929808).


Sign in / Sign up

Export Citation Format

Share Document